Tyche Industries Limited

TYCHE6

INE443B01012

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:01:00 2024-06-27 am EDT			5-day change	1st Jan Change
177.8 ^INR	+0.91%		-0.11%	-4.41%

May. 28	Tyche Industries Limited Recommends Final Dividend	CI
May. 28	Tyche Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Tyche Industries Limited Announces Resignation of Boosa Eshwar, Independent Director

September 12, 2023 at 01:33 am EDT

Tyche Industries Limited announced that Mr. Boosa Eshwar Independent Director of the Company has resigned from the office of Board of the Directors of the Company due to his preoccupations, with effect from close of business hours of September 11, 2023.

Latest news about Tyche Industries Limited

Tyche Industries Limited Recommends Final Dividend	May. 28	CI
Tyche Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 28	CI
Tyche Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Tyche Industries to Undertake Maintenance Activities at Kakinada, India Plant	Jan. 14	MT
Tyche Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 10	CI
Tyche Industries Limited Announces Resignation of Boosa Eshwar, Independent Director	23-09-12	CI
Tyche Industries Board Declares Dividend for Fiscal 2023	23-09-05	MT
Tyche Industries Limited Approves Dividend on the Equity Shares for the Financial Year Ended March 31, 2023	23-08-30	CI
Tyche Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Tyche Industries Limited Announces Management Changes	23-08-01	CI
Tyche Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-27	CI
Tyche Industries Limited Recommends Final Dividend	23-05-27	CI
Tyche Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Tyche Industries Declares Dividend for Fiscal 2023	22-10-13	MT
Tyche Industries Limited Declares Dividend for the Financial Year 2021-22	22-10-13	CI
Tyche Industries Limited Approves Dividend for the Financial Year Ended March 31, 2022	22-10-01	CI
Tyche Industries Limited Recommends Dividend for the Financial Year Ended March 31, 2022	22-09-06	CI
Tyche Industries Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-30	CI
Tyche Industries Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-30	CI
Tyche Industries Limited Recommends Final Dividend	22-05-30	CI
Tyche Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Tyche Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-12	CI
Tyche Industries Limited Approves Dividend for the Financial Year Ended March 31, 2021	21-10-01	CI
Tyche Industries Limited Proposes Dividend for the Financial Year Ended March 31, 2021	21-09-09	CI
Tyche Industries Limited Announces to Pay Environmental Compensation of INR 6,336,400 to Central Pollution Control Board	21-08-14	CI

Chart Tyche Industries Limited

Duration

Period

More charts

Company Profile

Tyche Industries Limited is an India-based company engaged in manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates of APIs. The Company operates through the Bulk Drugs segment. Its APIs include Sertraline HCI, Racecadotril, Palonosetron HCI, Silodosin, Solifenacin Succinate, Tamsulosin HCI, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide Fumarate, Atazanavir, Rupatadine Fumarate, Glucosamine HCI, Glucosamine Sulfate KCL, Glucosamine Sulfate NaCl, Nitrofurantoin Monohydrate, Nitrofurantoin Anhydrous and Nitrofurantoin Macrocrystal and others. Its intermediates include 4-(3,4-Dichlorophenyl)-1-tetralone, 1-Benzylpiperidine-4-Carboxaldehyde (BPCA), 3-Hydroxymethyl quinuclidine Hcl, and others. Its chiral intermediates include S-(+)-3-Quinuclidinol, R-(-)-3-Quinuclidinol and others. The Company's nutraceuticals include Glucosamine Hydrochloride, Glucosamine Sulfate Potassium Chloride and Glucosamine Sulfate Sodium Chloride.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TYCHE INDUSTRIES LIMITED	-4.41%	21.6M
ELI LILLY AND COMPANY	+54.85%	811B
NOVO NORDISK A/S	+43.62%	640B
JOHNSON & JOHNSON	-6.99%	353B
MERCK & CO., INC.	+17.96%	333B
ABBVIE INC.	+8.43%	302B
ASTRAZENECA PLC	+16.30%	246B
ROCHE HOLDING AG	+2.41%	225B
NOVARTIS AG	+12.47%	218B
AMGEN INC.	+9.07%	168B